

Eduardo Diaz-Rubio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11447703/publications.pdf>

Version: 2024-02-01

109
papers

9,061
citations

100601

38
h-index

45040

94
g-index

110
all docs

110
docs citations

110
times ranked

10412
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer. <i>Cancer Biomarkers</i> , 2022, 34, 201-210.	0.8	2
2	Behavioural and structural interventions in cancer prevention: towards the 2030 SDG horizon. <i>Molecular Oncology</i> , 2021, 15, 801-808.	2.1	7
3	First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. <i>Drugs and Aging</i> , 2021, 38, 219-231.	1.3	3
4	Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). <i>European Journal of Surgical Oncology</i> , 2021, , .	0.5	2
5	FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISION-1 trial. <i>ESMO Open</i> , 2020, 5, e000944.	2.0	32
6	Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected. <i>Clinical Colorectal Cancer</i> , 2020, 19, e110-e116.	1.0	20
7	First-line biological agents plus chemotherapy in elderly patients with metastatic colorectal cancer: A retrospective pooled analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4017-4017.	0.8	2
8	Contribution of New Adenomatous Polyposis Predisposition Genes in an Unexplained Attenuated Spanish Cohort by Multigene Panel Testing. <i>Scientific Reports</i> , 2019, 9, 9814.	1.6	9
9	A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 378-383.	2.9	2
10	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	2.8	6
11	Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. <i>Scientific Reports</i> , 2019, 9, 8976.	1.6	34
12	Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report. <i>Journal of Medical Genetics</i> , 2019, 56, 453-460.	1.5	30
13	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
14	Tumour location and efficacy of first-line EGFR inhibitors in wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials. <i>ESMO Open</i> , 2019, 4, e000599.	2.0	11
15	Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥ baseline circulating tumor cells (bCTCs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3507-3507.	0.8	17
16	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 560-567.	3.0	206
17	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018, 110, 638-648.	3.0	90
18	SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2 α . <i>Nature Communications</i> , 2018, 9, 575.	5.8	46

#	ARTICLE	IF	CITATIONS
19	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1464-1470.	2.9	62
20	Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition. <i>PLoS ONE</i> , 2018, 13, e0203885.	1.1	24
21	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>European Journal of Cancer</i> , 2018, 103, 205-213.	1.3	13
22	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	1.3	29
23	Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay. <i>Journal of Clinical Oncology</i> , 2018, 36, 592-592.	0.8	2
24	Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database. <i>Journal of Clinical Oncology</i> , 2018, 36, 612-612.	0.8	2
25	Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis. <i>Oncotarget</i> , 2018, 9, 10272-10283.	0.8	7
26	Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. <i>BMC Cancer</i> , 2017, 17, 210.	1.1	59
27	Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome. <i>PLoS ONE</i> , 2017, 12, e0187312.	1.1	10
28	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017, 35, 1929-1937.	0.8	37
29	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database. <i>Journal of Clinical Oncology</i> , 2017, 35, 3535-3535.	0.8	6
30	Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database. <i>Journal of Clinical Oncology</i> , 2017, 35, 675-675.	0.8	4
31	An individual patient data (IPD) meta-analysis of the impact of thrombocytosis (↑plts) on overall survival (OS) whilst using an intermittent chemotherapy (iCTx) strategy in advanced colorectal cancer (aCRC). <i>Journal of Clinical Oncology</i> , 2017, 35, e15044-e15044.	0.8	0
32	Study on compliance with breakthrough cancer pain guidelines by medical oncologists in Spain. <i>Journal of Clinical Oncology</i> , 2017, 35, e18260-e18260.	0.8	0
33	BRCA2 gene mutations and coagulation-associated biomarkers. <i>Thrombosis and Haemostasis</i> , 2016, 115, 415-423.	1.8	8
34	Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine + Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series. <i>Clinical Colorectal Cancer</i> , 2016, 15, 128-134.	1.0	3
35	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> , The, 2016, 17, 1709-1719.	5.1	442
36	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 144-150.	0.8	116

#	ARTICLE	IF	CITATIONS
37	Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database.. Journal of Clinical Oncology, 2016, 34, 656-656.	0.8	4
38	Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database.. Journal of Clinical Oncology, 2016, 34, 658-658.	0.8	0
39	Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction. Translational Research, 2015, 166, 783-787.	2.2	7
40	Gastric and esophageal metastases in renal cell carcinoma: systematic review and management options. International Cancer Conference Journal, 2015, 4, 1-12.	0.2	4
41	BRCA1 Alternative splicing landscape in breast tissue samples. BMC Cancer, 2015, 15, 219.	1.1	17
42	Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. Molecular Diagnosis and Therapy, 2015, 19, 397-408.	1.6	24
43	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	0.8	87
44	Concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for HER2 determination and correlation with clinical and pathological data.. Journal of Clinical Oncology, 2015, 33, e11616-e11616.	0.8	1
45	Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.. Journal of Clinical Oncology, 2015, 33, 3555-3555.	0.8	0
46	Incidence, classification and diagnosis of hyponatremia in patients admitted to the oncology ward.. Journal of Clinical Oncology, 2015, 33, e20656-e20656.	0.8	1
47	Developing standards and indicators for quality improvement for cancer patients in Spain.. Journal of Clinical Oncology, 2015, 33, e17718-e17718.	0.8	0
48	Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?. World Journal of Gastroenterology, 2014, 20, 6092.	1.4	27
49	About 1% of the breast and ovarian Spanish families testing negative for <i>BRCA1</i> and <i>BRCA2</i> are carriers of <i>RAD51D</i> pathogenic variants. International Journal of Cancer, 2014, 134, 2088-2097.	2.3	24
50	Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. Human Molecular Genetics, 2014, 23, 3666-3680.	1.4	96
51	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2014, 15, 406-414.	5.1	703
52	Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer. Familial Cancer, 2014, 13, 109-119.	0.9	14
53	Capillary Electrophoresis Analysis of Conventional Splicing Assays: IARC Analytical and Clinical Classification of 31 <i>BRCA2</i> Genetic Variants. Human Mutation, 2014, 35, 53-57.	1.1	25
54	Role of cetuximab in first-line treatment of metastatic colorectal cancer. World Journal of Gastroenterology, 2014, 20, 4208.	1.4	25

#	ARTICLE	IF	CITATIONS
55	Model of quality care indicators for patients with colorectal, lung, and breast cancer.. Journal of Clinical Oncology, 2014, 32, 241-241.	0.8	0
56	Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer. Oncologist, 2013, 18, 917-923.	1.9	41
57	Frequency and Variability of Genomic Rearrangements on MSH2 in Spanish Lynch Syndrome Families. PLoS ONE, 2013, 8, e72195.	1.1	7
58	Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.. Journal of Clinical Oncology, 2013, 31, 3533-3533.	0.8	2
59	Targeted Therapies in Older Patients with Metastatic Colorectal Cancer. , 2013, , 141-159.		0
60	First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study. Oncologist, 2012, 17, 339-345.	1.9	72
61	Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Oncologist, 2012, 17, 947-955.	1.9	77
62	Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer. Oncologist, 2012, 17, 1426-1428.	1.9	10
63	First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study. Oncologist, 2012, 17, 15-25.	1.9	192
64	Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer, 2012, 12, 260.	1.1	110
65	Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers. Journal of Cancer Research and Clinical Oncology, 2012, 138, 867-875.	1.2	15
66	Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin. Breast Cancer Research and Treatment, 2012, 133, 273-283.	1.1	13
67	Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study. PLoS ONE, 2012, 7, e47345.	1.1	38
68	Prevalence of low-penetrance KRAS (codons 12/13 and 61) and BRAF mutations in metastatic colorectal carcinoma.. Journal of Clinical Oncology, 2012, 30, e14147-e14147.	0.8	0
69	Efficacy and tolerability of trabectedin in heavily pretreated soft tissue sarcomas (STS).. Journal of Clinical Oncology, 2012, 30, e20513-e20513.	0.8	0
70	A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. Breast Cancer Research and Treatment, 2011, 129, 939-946.	1.1	42
71	Treatment recommendations for metastatic colorectal cancer. Clinical and Translational Oncology, 2011, 13, 162-178.	1.2	24
72	Analysis of the Oxidative Damage Repair Genes NUDT1, OGG1, and MUTYH in Patients from Mismatch Repair Proficient HNPCC Families (MSS-HNPCC). Clinical Cancer Research, 2011, 17, 1701-1712.	3.2	34

#	ARTICLE	IF	CITATIONS
73	Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. <i>Clinical and Translational Oncology</i> , 2010, 12, 533-542.	1.2	51
74	Reassessing the TARBP2 mutation rate in hereditary nonpolyposis colorectal cancer. <i>Nature Genetics</i> , 2010, 42, 817-818.	9.4	24
75	Alternative Splicing and Molecular Characterization of Splice Site Variants: BRCA1 c.591C>T as a Case Study. <i>Clinical Chemistry</i> , 2010, 56, 53-61.	1.5	21
76	Differential colorectal carcinogenesis: Molecular basis and clinical relevance. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 151.	0.8	53
77	Consensus on the treatment of pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , 2009, 11, 290-301.	1.2	4
78	Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 134-144.	2.0	44
79	Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis. <i>Anticancer Research</i> , 2009, 29, 4185-7.	0.5	17
80	Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. <i>European Journal of Cancer</i> , 2008, 44, 1229-1237.	1.3	68
81	Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 2013-2019.	0.8	2,735
82	Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 5910-5917.	0.8	149
83	Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2006-2012.	0.8	767
84	Molecular Analysis of Colorectal Cancer Tumors from Patients with Mismatch Repair-Proficient Hereditary Nonpolyposis Colorectal Cancer Suggests Novel Carcinogenic Pathways. <i>Clinical Cancer Research</i> , 2007, 13, 5729-5735.	3.2	43
85	Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5225-5232.	0.8	306
86	Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 4224-4230.	0.8	241
87	Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 103-107.	1.1	43
88	New target-based agents involve new clinical trial designs. <i>Clinical and Translational Oncology</i> , 2006, 8, 581-587.	1.2	0
89	Genomic Rearrangements at the BRCA1 Locus in Spanish Families with Breast/Ovarian Cancer. <i>Clinical Chemistry</i> , 2006, 52, 1480-1485.	1.5	60
90	Vascular Endothelial Growth Factor Inhibitors in Colon Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2006, 587, 251-275.	0.8	20

#	ARTICLE	IF	CITATIONS
91	Trastuzumab Associated with Successive Cytotoxic Therapies Beyond Disease Progression in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 325-329.	1.1	46
92	The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families. <i>Familial Cancer</i> , 2005, 4, 183-186.	0.9	12
93	Lack of Germ-line Mutations at the Specific BRCA1-IRIS Coding Sequence in 114 Spanish High-risk Breast/ovarian Families. <i>Familial Cancer</i> , 2005, 4, 317-319.	0.9	0
94	Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 3545-3551.	0.8	96
95	Two Consecutive Phase II Trials of Biweekly Oxaliplatin plus Weekly 48-Hour Continuous Infusion of Nonmodulated High-Dose 5-Fluorouracil as First-Line Treatment for Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 4, 384-389.	1.0	7
96	Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study. <i>Clinical Colorectal Cancer</i> , 2005, 5, 101-107.	1.0	55
97	Low prevalence of germline hMSH6 mutations in colorectal cancer families from Spain. <i>World Journal of Gastroenterology</i> , 2005, 11, 5770.	1.4	17
98	XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2084-2091.	0.8	465
99	New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers. <i>Oncologist</i> , 2004, 9, 282-294.	1.9	77
100	Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer. <i>Oncology Reports</i> , 2004, 12, 621.	1.2	15
101	Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer. <i>Oncology Reports</i> , 2004, 12, 621-9.	1.2	33
102	Analysis ofBRCA1andBRCA2genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects. <i>Human Mutation</i> , 2003, 22, 301-312.	1.1	154
103	Docetaxel extravasation: a case report. , 2003, 5, 47-48.		0
104	Prevalence of germline mutations ofMLH1 andMSH2 in hereditary nonpolyposis colorectal cancer families from Spain. <i>International Journal of Cancer</i> , 2002, 98, 774-779.	2.3	41
105	Clustering of cancer-related mutations in a subset ofBRCA1alleles: A study in the Spanish population. <i>International Journal of Cancer</i> , 2002, 100, 618-619.	2.3	6
106	Association betweenBRCA1andBRCA2mutations and cancer phenotype in Spanish breast/ovarian cancer families: Implications for genetic testing. <i>International Journal of Cancer</i> , 2002, 97, 466-471.	2.3	61
107	Stromelysin-1 promoter mutations impair gelatinase B activation in high microsatellite instability sporadic colorectal tumors. <i>Cancer Research</i> , 2002, 62, 3855-60.	0.4	19
108	Spanish family study on hereditary breast and/or ovarian cancer: Analysis of theBRCA1 gene. <i>International Journal of Cancer</i> , 2001, 91, 137-140.	2.3	26

#	ARTICLE	IF	CITATIONS
109	Clinical evaluation of the simultaneous blockade of the dopamine D-2, Histamine H-1, and muscarinic cholinergic receptors in cancer chemotherapy-induced emesis: Results of a controlled trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 18, 168-71.	1.1	6